Soligenix, Inc. (NASDAQ:SNGX) Short Interest Up 23.8% in September

Soligenix, Inc. (NASDAQ:SNGX) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 127,800 shares, a growth of 23.8% from the September 15th total of 103,200 shares. Approximately 5.6% of the company’s stock are short sold. Based on an average trading volume of 497,000 shares, the short-interest ratio is currently 0.3 days.

Soligenix Price Performance

Shares of NASDAQ:SNGX traded up $0.08 during midday trading on Tuesday, reaching $3.60. The company had a trading volume of 46,955 shares, compared to its average volume of 931,124. The stock’s fifty day moving average price is $3.79 and its 200-day moving average price is $4.92. Soligenix has a one year low of $1.83 and a one year high of $32.00. The stock has a market capitalization of $3.55 million, a P/E ratio of -0.31 and a beta of 1.84.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.80. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 256.12%. As a group, sell-side analysts forecast that Soligenix will post -5.1 earnings per share for the current year.

Institutional Trading of Soligenix

An institutional investor recently bought a new position in Soligenix stock. OLD National Bancorp IN purchased a new stake in shares of Soligenix, Inc. (NASDAQ:SNGX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. OLD National Bancorp IN owned about 1.01% of Soligenix at the end of the most recent quarter. Hedge funds and other institutional investors own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.